HIV prevention shot delivery methods put to the test
NCT ID NCT05374525
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed study looked at how to best offer cabotegravir, an HIV prevention shot, in US clinics. About 287 men and transgender men at risk for HIV took part. Researchers compared two ways of rolling out the shot to see which worked better in busy and less busy clinics.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
cabotegravir (injectable and oral tablets)
What this could lead to
If successful, this study could show the best way to offer cabotegravir PrEP in clinics, making HIV prevention easier and more accessible for at-risk groups.
What could go wrong
This is a completed Phase 4 implementation study, not a test of the drug itself. It focuses on clinic processes, not new efficacy or safety data, so results may not change current practice.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Los Angeles, California, 90036, United States
-
GSK Investigational Site
San Francisco, California, 94102, United States
-
GSK Investigational Site
Washington D.C., District of Columbia, 20005, United States
-
GSK Investigational Site
Miami, Florida, 33140, United States
-
GSK Investigational Site
Orlando, Florida, 32806, United States
-
GSK Investigational Site
Pensacola, Florida, 32503, United States
-
GSK Investigational Site
Sarasota, Florida, 34237, United States
-
GSK Investigational Site
Bridgeport, Kansas, 06605, United States
-
GSK Investigational Site
Boston, Massachusetts, 02215, United States
-
GSK Investigational Site
Columbia, Missouri, 65212, United States
-
GSK Investigational Site
St Louis, Missouri, 63117, United States
-
GSK Investigational Site
Rochester, New York, 14607, United States
-
GSK Investigational Site
The Bronx, New York, 10467, United States
-
GSK Investigational Site
Philadelphia, Pennsylvania, 19123, United States
-
GSK Investigational Site
Charleston, South Carolina, 29407, United States
-
GSK Investigational Site
Harlingen, Texas, 78550, United States
-
GSK Investigational Site
Seattle, Washington, 98104, United States